This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: EAS Academy

Themed Short Track: New approaches to LDL lowering.

Wednesday 8 January 2020   (0 Comments)
Share |

Introducing Themed Short Track

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses,
putting them together to provide up-to-date perspectives on a given current topic.

This month’s Short Track topic is New approaches to LDL lowering

This is a workshop held at the 87th EAS Congress in Maastricht 2019. The workshop included three lectures. An introductory presentation discussed the naturally randomized genetic evidence suggesting that the effect of various hypolipidemic drugs in reducing ASCVD is independent on their lipid lowering mechanism. The following 2 lectures were focused on the Bempedoic acid, a new very promising agent that reduces LDL-C in animal models as well as in humans.

To the SHORT TRACK New approaches to LDL lowering >>

These presentations is open for EAS members only. Register as an EAS individual member and the whole ACADEMY is open for you.

How to register as an EAS member >

The genetic evidence for inhibiting the cholesterol pathway to control LDL cholesterol

This presentation was given by Dr. Brian Ference, Professor and Director of Research in Translational Therapeutics Executive Director, Centre for Naturally Randomized Trials at the University of Cambridge, UK.

In his very comprehensive lecture, Professor Ference showed that Mendelian Randomization trials have precisely predicted the results of trials, in which different hypolipidemic drugs were used, suggesting that the effect of these drugs in reducing ASCVD is independent on the LDL-C lowering mechanism. He concluded that the naturally randomized genetic evidence suggests that the causal effect of all apoB-containing lipoproteins on the CVD risk is proportional to the change in apoB particle concentration and not the cholesterol or triglyceride content carried by these particles. Therefore the clinical benefit of any lipid lowering therapy should be proportional to the absolute reduction in plasma apoB concentration.   

To the presentation >>

Pharmacology of Bempedoic acid


The 2nd lecture of this workshop was given by Dr. Giuseppe Danilo Norata, Professor of Pharmacology at the Department of Excellence of Pharmacological and Biomolecular Sciences, University of Milan, Italy.

In his excellent talk, Professor Norata presented the mechanism of action of Bempedoic acid, a potent inhibitor of ATP citrate lyase in the liver, which significantly reduces LDL-C.
He also showed data on the LDL-C lowering effectiveness of Bempenoic acid in various animal models.
Professor Norata, discussed the effect of Bempedoic acid as an AMPK activator, emphasizing that this mechanism may not contribute to the drug-induced atheroprotection in animal models. Finally he shortly discussed the possible clinical implication of the above findings in humans.

To the presentation >>

Clinical experience with Bempedoic acid

The 3rd presentation of the workshop was given by Professor Christie Ballantyne, from the Center for Cardiomertabolic Disease Prevention, Baylor College of Medicine at Houston, Texas.

In his very comprehensive lecture Professor Ballantyne presented the phase 3 clinical development CLEAR Programme for Bempenoic acid.
He showed data on the LDL-C lowering effect as well as the efficacy and safety of Bempenoic acid administered in hyperlipidemic patients on top of ezetimibe or statin or the combination of ezetimibe plus statin.
He also presented the design of the CLEAR Outcomes trial, a randomized double-blind placebo-controlled study aiming to assess the effects of bempenoic acid on the occurrence of major CV events in statin intolerant patients with, or being at high risk for CVD.

To the presentation >>

Membership Software Powered by YourMembership  ::  Legal